Top

Current Atherosclerosis Reports

Published in:

08-08-2023 | Coronary Heart Disease

Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis

Authors: Young Seo Lee, Ji Won Park, Minjin Joo, Sumin Moon, Kyungim Kim, Myeong Gyu Kim

Published in: Current Atherosclerosis Reports | Issue 10/2023

Abstract

Purpose of Review

To investigate the effects of omega-3 fatty acids on flow-mediated dilatation (FMD) and carotid intima-media thickness (CIMT) and explore the factors influencing these effects.

Recent Findings

FMD was significantly higher in the omega-3 fatty acid group compared to the control group (mean difference = 0.90%; p = 0.0003). In particular, the subgroup with CHD (both EPA + DHA < 1 g/day and ≥ 1 g/day) and the subgroup without CHD but with CHD risk factors (only EPA + DHA ≥ 1 g/day) showed significantly increased FMD after supplementation of omega-3 fatty acids. CIMT was not significantly different between the omega-3 fatty acid and control groups (standardized mean difference = -0.08; p = 0.26). Subgroup analysis of CHD patients was not conducted because of the limited number of studies.

Summary

Intake of omega-3 fatty acids improved FMD in patients with CHD and patients with risk factors for CHD. Further research is needed on the effects of omega-3 fatty acids on CIMT.

Available only for authorised users

World Health Organization. Cardiovascular diseases (CVDs). 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Assessed on 13 Oct 2022.

Center for Disease Control and Prevention. Heart Disease Facts. 2022. https://www.cdc.gov/heartdisease/facts.htm. Assessed on 13 Oct 2022.

British Heart Foundation. Heart & Circulatory Disease Statistics 2021. 2021. https://www.bhf.org.uk/what-we-do/our-research/heart-statistics/heart-statistics-publications/cardiovascular-disease-statistics-2021. Assessed on 13 Oct 2022.

Goodfellow J, Bellamy MF, Ramsey MW, Jones CJH, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000;35(2):265–70. https://doi.org/10.1016/S0735-1097(99)00548-3.CrossRefPubMed

Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540–50. https://doi.org/10.1016/S0140-6736(10)60445-X.CrossRefPubMed

Filion KB, El Khoury F, Bielinski M, Schiller I, Dendukuri N, Brophy JM. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24. https://doi.org/10.1186/1471-2261-10-24.CrossRefPubMedPubMedCentral

Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441–5.PubMed

Feuchtner G, Langer C, Barbieri F, Beyer C, Dichtl W, Friedrich G, et al. The effect of omega-3 fatty acids on coronary atherosclerosis quantified by coronary computed tomography angiography. Clin Nutr. 2021;40(3):1123–9. https://doi.org/10.1016/j.clnu.2020.07.016.CrossRefPubMed

Liao J, Xiong Q, Yin Y, Ling Z, Chen S. The effects of fish oil on cardiovascular diseases: systematical evaluation and recent advance. Front Cardiovasc Med. 2021;8:802306. https://doi.org/10.3389/fcvm.2021.802306.CrossRefPubMed

10.

Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18. https://doi.org/10.1056/NEJMoa1203859.CrossRefPubMed

11.

Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–50. https://doi.org/10.1056/NEJMoa1804989.CrossRefPubMed

12.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRefPubMed

13.

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the strength randomized clinical trial. JAMA. 2020;324(22):2268–80. https://doi.org/10.1001/jama.2020.22258.CrossRefPubMedPubMedCentral

14.

Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views. 2017;18(3):109–14. https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17.CrossRefPubMedPubMedCentral

15.

Iaccarino L, Bettio S, Zen M, Nalotto L, Gatto M, Ramonda R, et al. Premature coronary heart disease in SLE: can we prevent progression? Lupus. 2013;22(12):1232–42. https://doi.org/10.1177/0961203313492871.CrossRefPubMed

16.

Norman PE, Eikelboom JW, Hankey GJ. Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J Aust. 2004;181(3):150–4. https://doi.org/10.5694/j.1326-5377.2004.tb06206.x.CrossRefPubMed

17.

Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19(9):927–33. https://doi.org/10.1097/01.aids.0000171406.53737.f9.CrossRefPubMed

18.

Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33(10):1190–200. https://doi.org/10.1093/eurheartj/ehr453.CrossRefPubMed

19.

Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9(4):331–9. https://doi.org/10.2174/1573403x10666140214122234.CrossRefPubMedPubMedCentral

20.

Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013;162(4):237–51. https://doi.org/10.1016/j.trsl.2013.05.001.CrossRefPubMed

21.

Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American heart association and american college of cardiology foundation. Circulation. 2011;124(22):2458–73. https://doi.org/10.1161/CIR.0b013e318235eb4d.CrossRefPubMed

22.

Li X, Liu M, Sun R, Zeng Y, Chen S, Zhang P. Atherosclerotic coronary artery disease: The accuracy of measures to diagnose preclinical atherosclerosis. Exp Ther Med. 2016;12(5):2899–902. https://doi.org/10.3892/etm.2016.3710.CrossRefPubMedPubMedCentral

23.

Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50(5):397–404. https://doi.org/10.1046/j.1365-2125.2000.00277.x.CrossRefPubMedPubMedCentral

24.

Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–9. https://doi.org/10.1161/HYPERTENSIONAHA.110.167015.CrossRefPubMed

25.

Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997;129(1):111–8. https://doi.org/10.1016/s0021-9150(96)06018-2.CrossRefPubMed

26.

Raggi P, Stein JH. Carotid intima-media thickness should not be referred to as subclinical atherosclerosis: A recommended update to the editorial policy at Atherosclerosis. Atherosclerosis. 2020;312:119–210. https://doi.org/10.1016/j.atherosclerosis.2020.09.015.CrossRefPubMed

27.

Simon A, Megnien JL, Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol. 2010;30(2):182–5. https://doi.org/10.1161/ATVBAHA.109.196980.CrossRefPubMed

28.••

Chu Z, Wei Y, Hao Y, Wang J, Huang F, Hou M. Clinical effectiveness of fish oil on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(5):1339–48. https://doi.org/10.1016/j.numecd.2020.12.033. Findings from this study suggest that fish oil supplementation had a beneficial effect on pulse wave velocity.CrossRefPubMed

29.

Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr. 2011;106(7):974–80. https://doi.org/10.1017/S0007114511002819.CrossRefPubMed

30.

Tousoulis D, Plastiras A, Siasos G, Oikonomou E, Verveniotis A, Kokkou E, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232(1):10–6. https://doi.org/10.1016/j.atherosclerosis.2013.10.014.CrossRefPubMed

31.

Toyama K, Nishioka T, Isshiki A, Ando T, Inoue Y, Kirimura M, et al. Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014;28(1):53–9. https://doi.org/10.1007/s10557-013-6496-3.CrossRefPubMed

32.

Kajbaf MH, Khorvash F, Mortazavi M, Shahidi S, Moeinzadeh F, Farajzadegan Z, et al. Does Omega-3 supplementation decrease carotid intima-media thickening in hemodialysis patients? J Res Pharm Pract. 2016;5(4):252–6. https://doi.org/10.4103/2279-042X.192451.CrossRefPubMedPubMedCentral

33.

Angerer P, Kothny W, Störk S, Von Schacky C. Effect of dietary supplementation with ω-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res. 2002;54(1):183–90. https://doi.org/10.1016/s0008-6363(02)00229-8.CrossRefPubMed

34.•

O’Mahoney LL, Dunseath G, Churm R, Holmes M, Boesch C, Stavropoulos-Kalinoglou A, et al. Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovasc Diabetol. 2020;19(1):127. https://doi.org/10.1186/s12933-020-01094-5. Findings from this study suggest that omega-3 fatty acids supplementation for 6-months does not improve CIMT and FMD in patients with type 1 diabetes.CrossRefPubMedPubMedCentral

35.

Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536–43. https://doi.org/10.1016/j.atherosclerosis.2012.01.006.CrossRefPubMed

36.

Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on coronary restenosis, intima-media thickness, and exercise tolerance: a systematic review. Atherosclerosis. 2006;184(2):237–46. https://doi.org/10.1016/j.atherosclerosis.2005.06.042.CrossRefPubMed

37.

Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.CrossRefPubMed

38.

Deeks JJ, Higgins JP, Altman DG. 10.3 A generic inverse-variance approach to meta-analysis. 2022. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-3. Assessed on 13 Oct 2022.

39.

Pathak M, Dwivedi SN, Thakur B, Vishnubhatla S. Methods of estimating the pooled effect size under meta-analysis: A comparative appraisal. Clin Epidemiol Glob Health. 2020;8:105–12. https://doi.org/10.1016/j.cegh.2019.05.004.CrossRef

40.

Higgins JP, Li T, Deek JJ. Chapter 6: Choosing effect measures and computing estimates of effect. 2022. https://training.cochrane.org/handbook/current/chapter-06. Assessed on 13 Oct 2022.

41.

Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135.CrossRefPubMedPubMedCentral

42.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. https://doi.org/10.1136/bmj.39489.470347.AD.CrossRefPubMedPubMedCentral

43.

Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003;166:85–93. https://doi.org/10.1016/s0021-9150(02)00307-6.CrossRefPubMed

44.

Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil. 2006;13:325–33. https://doi.org/10.1097/01.hjr.0000209817.28444.fb.CrossRefPubMed

45.

Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa O, Kinoshita J, et al. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191:162–7. https://doi.org/10.1016/j.atherosclerosis.2006.03.005.CrossRefPubMed

46.

Shah AP, Ichiuji AM, Han JK, Traina M, El-Bialy A, Meymandi SK, et al. Cardiovascular and endothelial effects of fish oil supplementation in healthy volunteers. J Cardiovasc Pharmacol Ther. 2007;12:213–9. https://doi.org/10.1177/1074248407304749.CrossRefPubMed

47.

Wright SA, O’Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008;67:841–8. https://doi.org/10.1136/ard.2007.077156.CrossRefPubMed

48.

Schiano V, Laurenzano E, Brevetti G, De Maio JI, Lanero S, Scopacasa F, et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr. 2008;27:241–7. https://doi.org/10.1016/j.clnu.2007.11.007.CrossRefPubMed

49.

Rizza S, Tesauro M, Cardillo C, Galli A, Iantorno M, Gigli F, et al. Fish oil supplementation improves endothelial function in normoglycemic offspring of patients with type 2 diabetes. Atherosclerosis. 2009;206:569–74. https://doi.org/10.1016/j.atherosclerosis.2009.03.006.CrossRefPubMedPubMedCentral

50.

Wong CY, Yiu KH, Li SW, Lee S, Tam S, Lau CP, et al. Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus. Diabet Med. 2010;27:54–60. https://doi.org/10.1111/j.1464-5491.2009.02869.x.CrossRefPubMed

51.

Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr. 2010;91:808–13. https://doi.org/10.3945/ajcn.2009.28374.CrossRefPubMed

52.

Skulas-Ray AC, Kris-Etherton PM, Harris WS, VandenHeuvel JP, Wagner PR, West SG. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr. 2011;93:243–52. https://doi.org/10.3945/ajcn.110.003871.CrossRefPubMed

53.

Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr. 2011;94:973–80. https://doi.org/10.3945/ajcn.111.018036.CrossRefPubMed

54.

Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3- polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J. 2011;161(915):e1-9. https://doi.org/10.1016/j.ahj.2011.02.011.CrossRef

55.

Haberka M, Mizia-Stec K, Mizia M, Janowska J, Gieszczyk K, Chmiel A, et al. N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction. Clin Nutr. 2011;30:79–85. https://doi.org/10.1016/j.clnu.2010.07.011.CrossRefPubMed

56.

Hileman CO, Carman TL, Storer NJ, Labbato DE, White CA, McComsey GA. Omega-3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses. 2012;28:649–55. https://doi.org/10.1089/aid.2011.0088.CrossRefPubMedPubMedCentral

57.

Koh KK, Quon MJ, Shin KC, Lim S, Lee Y, Sakuma I, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis. 2012;220:537–44. https://doi.org/10.1016/j.atherosclerosis.2011.11.018.CrossRefPubMed

58.

Bello KJ, Fang H, Fazeli P, Bolad W, Corretti M, Magder LS, et al. Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int. 2013;33:2789–96. https://doi.org/10.1007/s00296-013-2811-3.CrossRefPubMedPubMedCentral

59.

Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hâncu N, et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care. 2013;36:2466–74. https://doi.org/10.2337/dc12-2129.CrossRefPubMedPubMedCentral

60.

Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Verveniotis A, Plastiras A, et al. Effects of omega-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: A cross over study. Int J Cardiol. 2013;166:340–6. https://doi.org/10.1016/j.ijcard.2011.10.081.CrossRefPubMed

61.

Singhal A, Lanigan J, Storry C, Low S, Birbara T, Lucas A, et al. Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults. J Am Heart Assoc. 2013;2:e000283. https://doi.org/10.1161/JAHA.113.000283.CrossRefPubMedPubMedCentral

62.

Oh PC, Koh KK, Sakuma I, Lim S, Lee Y, Lee S, et al. Omega-3 fatty acid therapy dose-dependently and significantly decreased triglycerides and improved flow-mediated dilation, however, did not significantly improve insulin sensitivity in patients with hypertriglyceridemia. Int J Cardiol. 2014;176:696–702. https://doi.org/10.1016/j.ijcard.2014.07.075.CrossRefPubMed

63.

Miyoshi T, Noda Y, Ohno Y, Sugiyama H, Oe H, Nakamura K, et al. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial. Biomed Pharmacother. 2014;68:1071–7. https://doi.org/10.1016/j.biopha.2014.10.008.CrossRefPubMed

64.

Witte AV, Kerti L, Hermannstädter HM, Fiebach JB, Schreiber SJ, Schuchardt JP, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex. 2014;24:3059–68. https://doi.org/10.1093/cercor/bht163.CrossRefPubMed

65.

Grenon SM, Owens CD, Nosova EV, Hughes-Fulford M, Alley HF, Chong K, et al. Short-Term, high-dose fish oil supplementation increases the production of omega-3 fatty acid-derived mediators in patients with peripheral artery disease (the OMEGA-PAD I Trial). J Am Heart Assoc. 2015;4:e002034. https://doi.org/10.1161/JAHA.115.002034.CrossRefPubMedPubMedCentral

66.

Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016;246:13–20. https://doi.org/10.1016/j.atherosclerosis.2015.12.028.CrossRefPubMed

67.

Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, et al. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol. 2016;15:121. https://doi.org/10.1186/s12933-016-0437-y.CrossRefPubMedPubMedCentral

68.

Siniarski A, Haberka M, Mostowik M, Gołębiowska-Wiatrak R, Poręba M, Malinowski KP, et al. Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD). Atherosclerosis. 2018;271:148–55. https://doi.org/10.1016/j.atherosclerosis.2018.02.030.CrossRefPubMed

69.

Eide IA, Reinholt FP, Jenssen T, Hartmann A, Schmidt EB, Åsberg A, et al. Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. Am J Transplant. 2019;19:790–800. https://doi.org/10.1111/ajt.15080.CrossRefPubMed

70.

Hammer A, Moertl D, Schlager O, Matschuck M, Seidinger D, Koppensteiner R, et al. Effects of n-3 PUFA on endothelial function in patients with peripheral arterial disease: a randomised, placebo-controlled, double-blind trial. Br J Nutr. 2019;122:698–706. https://doi.org/10.1017/S0007114519001582.CrossRefPubMed

71.

Oikonomou E, Vogiatzi G, Karlis D, Siasos G, Chrysohoou C, Zografos T, et al. Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients. Clin Nutr. 2019;38:1188–97. https://doi.org/10.1016/j.clnu.2018.04.017.CrossRefPubMed

72.

Kim JS, Thomashow MA, Yip NH, Burkart KM, Lo Cascio CM, Shimbo D, et al. Randomization to omega-3 fatty acid supplementation and endothelial function in COPD: The COD-Fish randomized controlled trial. Chronic Obstructive Pulm Dis. 2020;8:41–53. https://doi.org/10.15326/jcopdf.8.1.2020.0132.CrossRef

73.

Morishima T, Tsuchiya Y, Padilla J, Ochi E. Eight weeks of fish oil supplementation does not prevent sitting-induced leg endothelial dysfunction. Appl Physiol Nutr Metab. 2020;45:55–60. https://doi.org/10.1139/apnm-2019-0138.CrossRefPubMed

74.

Bunout D, Barrera G, Hirsch S, Lorca E. A randomized, double-blind, placebo-controlled clinical trial of an omega-3 fatty acid supplement in patients with predialysis chronic kidney disease. J Renal Nutr: Off J Council Renal Nutr Natl Kidney Foundation. 2021;31:64–72. https://doi.org/10.1053/j.jrn.2020.04.004.CrossRef

75.

Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr. 2012;142(3):592s-s599. https://doi.org/10.3945/jn.111.155259.CrossRefPubMed

76.

Cheng Y, Sun Z, Ya X, Zhou L, Wang M, Wang X, et al. Effect of exercise training on arterial stiffness in obese and overweight children: a meta-analysis. Eur J Pediatr. 2022;181:2633–42. https://doi.org/10.1007/s00431-022-04489-6.CrossRefPubMed

77.

Gholami F, Nazari H, Alimi M. Cycle Training improves vascular function and neuropathic symptoms in patients with type 2 diabetes and peripheral neuropathy: A randomized controlled trial. Exp Gerontol. 2020;131:110799. https://doi.org/10.1016/j.exger.2019.110799.CrossRefPubMed

78.

Tangchaisuriya P, Chuensiri N, Tanaka H, Suksom D. Physiological adaptations to high-intensity interval training combined with blood flow restriction in masters road cyclists. Med Sci Sports Exerc. 2022;54:830–40. https://doi.org/10.1249/MSS.0000000000002857.CrossRefPubMed

79.

Lee K, Kang I, Mark WJ, Mortimer J, Sattler F, Salem G, et al. Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study. Breast Cancer Res Treat. 2019;177:477–85. https://doi.org/10.1007/s10549-019-05332-7.CrossRefPubMedPubMedCentral

80.

Pacifico L, Arca M, Anania C, Cantisani V, Di Martino M, Chiesa C. Arterial function and structure after a 1-year lifestyle intervention in children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:1010–6. https://doi.org/10.1016/j.numecd.2012.08.003.CrossRefPubMed

81.

Timár O, Szekanecz Z, Kerekes G, Végh J, Oláh AV, Nagy G, et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis–a prospective case-series study. Arthritis Res Ther. 2013;15:R105. https://doi.org/10.1186/ar4285.CrossRefPubMedPubMedCentral

Title: Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis
Authors: Young Seo Lee
Ji Won Park
Minjin Joo
Sumin Moon
Kyungim Kim
Myeong Gyu Kim
Publication date: 08-08-2023
Publisher: Springer US
Keyword: Coronary Heart Disease
Published in: Current Atherosclerosis Reports / Issue 10/2023
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-023-01137-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 10/2023

Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins

Fixed Combination for the Treatment of Dyslipidaemia

Treatment of Lp(a): Is It the Future or Are We Ready Today?

Mechanosensing and Mechanosignal Transduction in Atherosclerosis

Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries

The TICE Pathway: Mechanisms and Potential Clinical Applications

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage